Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06364501
Other study ID # KH801
Secondary ID
Status Not yet recruiting
Phase Phase 1
First received
Last updated
Start date May 1, 2024
Est. completion date May 1, 2030

Study information

Verified date April 2024
Source Chengdu Kanghong Pharmaceutical Group Co., Ltd.
Contact Erwei Song
Phone 18982182468
Email 022516@cnkh.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

KH801 is a injection used for advanced solid tumors which must be diluted with 5% Dextrose Or 0.9% sodium chloride Injection. This study is expected to include a total of approximately 17-42 participants.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 17
Est. completion date May 1, 2030
Est. primary completion date May 1, 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Signed informed consent voluntarily. 2. Age = 18 years old (subject to the date of signing the informed consent form), both genders. 3. With an expected life expectancy of = 3 months. 4. With an ECOG(Eastern Cooperative Oncology Group Performance Status) performance status score of 0-1. 5. Patients with locally advanced unresectable or metastatic malignant solid tumors confirmed by histology, (including but not limited to breast cancer, lung cancer, ovarian cancer, colorectal cancer and other solid tumors) who failed or unable to tolerate previous standard treatments. 6. With at least one measurable target lesion was evaluated according to RECIST v1.1 criteria. Measurable target lesions were defined as non-lymph node lesions with the longest single diameter = 10mm, or lymph node lesions with a short diameter = 15mm. 7. The organ function reserve of patients before enrollment should meet the following laboratory test values: 7.1 Hematology: Neutrophil count = 1.5 × 109/L, hemoglobin = 90g/L, platelets = 100 × 109/L ( Use of hematopoietic growth factor drugs within the first two weeks of screening is not allowed to improve the detection value and meet inclusion criteria); 7.2 Liver function: Total bilirubin = 1.5 x ULN, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) = 2.5 x ULN (if there is liver metastasis or hepatocellular carcinoma(HCC), ALT and AST = 5 x ULN); 7.3 Renal function: serum creatinine = 1.5 × ULN, or creatinine clearance rate = 50 milliliter(mL)/min (calculated using Cockcroft Gault formula, see Appendix 5 for details); Urinary protein<2+, or urinary protein = 2+and 24-hour urine protein quantification<1g; 7.4 Coagulation function: prothrombin time (PT), international normalized ratio (INR), and activated partial thromboplastin time (APTT) = 1.5 x ULN (except for patients receiving anticoagulant therapy). 8. Female patients with fertility or male patients with partners with fertility must start using efficient contraceptive measures 7 days before the first dose and continue until 6 months after the last dose (excluding those who have undergone sterilization surgery (such as bilateral tubal ligation, oophorectomy, or hysterectomy). Female patients with fertility must have a negative blood pregnancy test within 7 days before the first administration. 9. Patients must recover from acute toxic reactions caused by previous anti-tumor treatments (CTCAE = level 1), except for the following situations: a. hair loss; b. Skin pigmentation; c. Grade 2 ande below neurotoxicity; d. The long-term toxicity caused by radiotherapy cannot be restored according to the judgment of the researchers. Exclusion Criteria: 1. Patients with primary central nervous system tumors and central nervous system (CNS) metastases (except for patients who have been clinically stable for = 4 weeks after previous surgery or radiotherapy and have discontinued corticosteroid treatment). 2. Patients with interstitial lung disease (ILD) (excluding local interstitial pneumonia caused by radiotherapy), severe chronic obstructive pulmonary disease, and severe pulmonary insufficiency. 3. Positive for human immunodeficiency virus antibody (HIVAb), active hepatitis B virus infection (HBV-DNA copy number = ULN) or active hepatitis C virus infection (HCV-RNA = ULN), as well as other severe active infections that have not been controlled or require treatment. 4. Individuals who have previously received cluster of differentiation 24(CD24) targeted therapy. 5. Previous history of receiving allogeneic hematopoietic stem cell transplantation or other organ transplantation; 6. Patients who have received any anti-tumor treatment (including chemotherapy, hormone therapy, radiotherapy, immunotherapy, or biological therapy) within 4 weeks or 5 half lives of drugs previously used (whichever is longer) before the first dose. 7. Participated in other clinical trials within 4 weeks prior to the first administration. 8. Female subjects in lactation or pregnancy. 9. Previous or current mental/neurological disorders are not limited to schizophrenia, delusions, phobias, obsessive-compulsive disorder, Alzheimer's disease, behavioral and volitional disorders, postpartum mental disorders, paranoid mental disorders, and various organic disorders accompanied by mental disorders. 10. Active autoimmune diseases within the past 2 years (excluding vitiligo, Graves disease, Hashimoto's thyroiditis, or psoriasis that do not require systemic treatment). 11. Have suffered from other malignant tumors within the past 5 years, except for the following situations: 11.1 Cured non melanoma skin malignant tumors; 11.2 Cervical carcinoma in situ; 11.3 Cured stage I endometrial cancer; 11.4 Curative breast ductal carcinoma in situ or lobular carcinoma in situ, and currently not receiving any systemic treatment; 11.5 Localized prostate cancer, papillary thyroid cancer, or follicular thyroid cancer that has undergone radical surgery and is currently considered cured/long-term stable. 12. Accompanied by active cardiovascular and cerebrovascular diseases: 12.1 Has experienced myocardial infarction, stroke, bypass surgery, or stent placement within 6 months prior to the first administration; 12.2 Congestive heart failure New York Heart Association(NYHA) III-IV; 12.3 Left ventricular ejection fraction (LVEF)<50%; 12.4 Corrected QT interval(QTC) was prolonged (female>470ms, male>450ms); 12.5 Unstable angina that cannot be controlled by medication, severe arrhythmias that require medication treatment (excluding atrial fibrillation or paroxysmal supraventricular tachycardia); 12.6 Hypertension (systolic blood pressure = 160 millimeters of mercury (mmHg) or diastolic blood pressure = 100mmHg) that cannot be controlled after standardized drug treatment, as well as a history of hypertensive crisis or hypertensive encephalopathy; 12.7 Suffering from major vascular diseases (such as aortic aneurysm, aortic dissection). 13. Patients with deep vein thrombosis (except for those with stable intermuscular vein thrombosis or infusion port thrombosis assessed by the investigators), pulmonary embolism or other serious thromboembolism, or patients with deep vein thrombosis, pulmonary embolism or other serious thromboembolism within 6 months before enrollment, and who are assessed by the investigator to be at risk of recurrence. 14. Patients allergic to immunoglobulin or any component of KH801 injection. 15. Patients who have received live attenuated vaccine within 4 weeks before enrollment or plan to receive live attenuated vaccine during the study period. 16. Patients who have undergone major surgery within 4 weeks before the first dose or plan to have major surgery during the study period. 17. Patients who have any other conditions that render them inappropriate for inclusion in the investigator's opinion.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
KH801
KH801 is an injection solution

Locations

Country Name City State
China West China Second University Hospital,Sichuan University/West China Women's and Children's Hospital Chengdu Sichuan
China Sun Yat-sen Memorial Hospital,Sun Yat-sen University Guangzhou Guangdong
China Central Hospital Affiliated To Shandong First Medical University Jinan Shandong
China Peking University Cancer Hospital Peking Beijing

Sponsors (1)

Lead Sponsor Collaborator
Beijing Kanghong Biopharmaceutical Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Other Objective Response Rate(ORR) Objective Response Rate(ORR)is defined as the percentage of participants, who has a complete response (CR) (disappearance of all target lesions) or partial response (PR) (at least a 30% decrease in the sum of diameters of target lesions). The percentage of participants who experiences a confirmed CR or PR is according to RECIST 1.1 through study completion, an average of 1 year
Other Disease Control Rate (DCR) The Disease Control Rate (DCR) is defined as the percentage of participants who has a CR, PR, or Stable Disease (SD): neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD): at least a 20% increase in the sum of diameters of target lesions and an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD]). through study completion, an average of 1 year
Other Duration of Response (DOR) The Duration of Response (DOR) for a responder is defined as the time from the participant's initial objective response to the first date of either disease progression or death, whichever occurs first. through study completion, an average of 1 year
Other Median Progression-Free Survival (mPFS) Median progression free survival (mPFS) refers to the progression free survival that 50% of assessable patients can achieve through study completion, an average of 1 year
Other Overall Survival(OS) The overall survival period refers to the time period from the start of treatment in a patient's study (whether randomized or single arm trial) until death from any cause through study completion, an average of 1 year
Primary MTD Maximum tolerated dose (MTD) up to 4 weeks
Primary DLT Dose limiting toxicity (DLT) up to 4 weeks
Primary RP2D Recommended phase II dose (RP2D) up to 1 year
Secondary AE Adverse events 30 days after EOT,up to 1 year
Secondary Cmax Maximum serum concentration (Cmax) of KH801 will be investigated up to 12 weeks
Secondary Tmax Time to maximum serum concentration(Tmax) of KH801 will be investigated up to 12 weeks
Secondary T1/2 Half-life (T1/2) of KH801 will be investigated up to 12 weeks
Secondary AUC0-t AUC0-t is defined as area under the serum concentration-time curve from time 0 to the time of the last measurable concentration up to 12 weeks
Secondary CL Plasma clearance rate (Cl) is defined the volume of plasma per unit time in which drugs are completely eliminated. up to 12 weeks
Secondary AUC0-inf AUC0-inf is defined area under the blood drug concentration time curve from 0 to infinity up to 12 weeks
Secondary anti-drug antibody (ADA) The anti-drug antibody of KH801 up to 1 years
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04972981 - A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-901 in Participants With Selected Advanced Solid Tumors Phase 1
Completed NCT05086822 - A Study of Irinotecan Hydrochloride Liposome in Advanced Solid Tumors Phase 1
Completed NCT03260322 - A Multiple-dose Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors Phase 1
Completed NCT02526017 - Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers Phase 1
Recruiting NCT06040541 - Study of RMC-9805 in Participants With KRASG12D-Mutant Solid Tumors Phase 1
Recruiting NCT05862831 - Clinical Study of PM1003 in Phase I/IIa Treatment of Advanced Malignant Solid Tumors Phase 1/Phase 2
Recruiting NCT03641794 - Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Healthy Volunteers Phase 1
Terminated NCT03665129 - IPH5401 (Anti-C5aR) in Combination With Durvalumab in Patients With Advanced Solid Tumors Phase 1
Not yet recruiting NCT06413680 - A First-In Human (FIH) Trial to Find Out if REGN10597 is Safe and How Well it Works for Adult Participants With Advanced Solid Organ Malignancies Phase 1/Phase 2
Recruiting NCT05914116 - A Study of DB-1311 in Advanced/Metastatic Solid Tumors Phase 1/Phase 2
Completed NCT01693562 - A Phase 1/2 Study to Evaluate MEDI4736 Phase 1/Phase 2
Recruiting NCT04387916 - A Study of KC1036 in Patients With Advanced Solid Tumors Phase 1
Completed NCT04095273 - Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the Elimusertib in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug Phase 1
Not yet recruiting NCT03692520 - Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of SCT200 in Patients With Advanced Solid Tumors Phase 1
Completed NCT02997176 - An Open-Label Pharmacokinetics and Safety Study of Talazoparib (MDV3800) Phase 1
Recruiting NCT04446260 - A Study of SHR-A1811 in Subjects With Advanced Malignant Solid Tumors Phase 1
Recruiting NCT06239155 - A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors Phase 1/Phase 2
Terminated NCT02253992 - An Investigational Immuno-therapy Study to Determine the Safety of Urelumab Given in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkin's Lymphoma Phase 1/Phase 2
Recruiting NCT06076291 - An Open-label Study of SG1827 in Subjects With Advanced Solid Tumors Phase 1
Completed NCT03545971 - A Study of IBI310 for the Treatment of Patients With Advanced Solid Tumors. Phase 1